Clinical Trial Update: Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial update of Becotatug Vedotin (MRG003) in combination with a PD-1 inhibitor for EGFR-positive CPS≥1 resectable locally advanced head and neck squamo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Becotatug Vedotin (MRG003) (becotatug vedotin)
• PD-1 inhibitor

Snippet

Sponsor: Ming-Yuan Chen | Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING